New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
05:45 EDTAET, MYGNAetna BRCA testing policy bulletin not a change, says William Blair
William Blair says shares of Myriad Genetics (MYGN) dropped 2% Friday after Aetna (AET) issued a clinical policy bulletin update for BRCA testing that changed the word "Myriad" to "Laboratory." The firm believes the bulletin does not represent a change to the status quo since a number of labs now offer BRCA testing. William Blair keeps an Outperform rating on Myriad.
News For MYGN;AET From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2015
06:40 EDTMYGNStart-up to offer saliva test for breast cancer susceptibility, NY Times says
Subscribe for More Information
April 13, 2015
10:58 EDTAETCigna, Humana seen as potential takeover targets in Managed Care space
Subscribe for More Information
07:33 EDTAETJefferies sees low probability of WellCare, Centene buyouts
After running several acquisition scenarios for the Managed Care space, Jefferies says potential takeovers of WellCare (WCG) and Centene (CNC) are "hard to justify." The firm estimates acquirers will only be able to generate 1%-3% accretion from buying either company at a 20% premium to current share prices. The deal that makes the most financial sense is Aetna (AET) buying Cigna (CI), Jefferies says today in a note to investors. Also financially attractive would be a buyout of Humana (HUM) by either Anthem (ANTM) or Aetna, the firm adds. After analyzing the Managed Care space, it upgraded this morning shares of UnitedHealth (UNH) to Buy from Hold with a $141 price target. Jefferies also has Buy ratings on Aetna, Anthem, Health Net (HNT) and Molina Healthcare (MOH).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use